| Literature DB >> 27664059 |
Brian C Lund1,2, Mary E Charlton3,4, Alan N West5,6.
Abstract
BACKGROUND: Utilization of private sector healthcare services among dual enrolled veterans with private healthcare insurance plans (PHIP) has not been well-characterized. Concurrent use of Veterans Health Administration (VHA) and non-VHA pharmacies may increase risk for adverse outcomes. Thus, the objectives of this study were to determine the extent to which dual VHA-PHIP enrollees obtain medications through VHA and non-VHA pharmacies and to characterize medications obtained through non-VHA pharmacies.Entities:
Keywords: Access to care; Drugs; Health insurance; Veterans
Year: 2016 PMID: 27664059 PMCID: PMC5035463 DOI: 10.1186/s12913-016-1773-z
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Patient characteristics
| Characteristic | FY 2002 | FY 2010 | Statistics |
|---|---|---|---|
|
|
|
| |
| Age in years, mean (S.D.) | 51.2 (9.2) | 52.4 (11.0) |
|
| Age group, |
| ||
| < 35 years | 335 (8.3) | 716 (10.1) | |
| 35–44 years | 490 (12.2) | 963 (13.6) | |
| 45–54 years | 1556 (38.7) | 1218 (17.2) | |
| 55–64 years | 1641 (40.8) | 4190 (59.1) | |
| Sex, |
| ||
| Male | 3879 (96.4) | 6693 (94.4) | |
| Female | 143 (3.6) | 394 (5.6) | |
| Marital Status, |
| ||
| Married | 1295 (32.2) | 2677 (37.8) | |
| Never Married | 144 (3.6) | 294 (4.2) | |
| Divorced or Widowed | 2323 (57.8) | 3609 (50.9) | |
| Unknown | 260 (6.5) | 507 (7.2) | |
| Residence, |
| ||
| Urban | 1308 (32.5) | 2819 (39.8) | |
| Rural | 2702 (67.2) | 4214 (59.5) | |
| Unknown | 12 (0.3) | 54 (0.8) | |
| Service Connection, |
| ||
| None | 2439 (60.6) | 4408 (62.2) | |
| 1–10 % | 568 (14.1) | 1079 (15.2) | |
| 11–80 % | 837 (20.8) | 1397 (19.7) | |
| 81–100 % | 54 (1.3) | 92 (1.3) | |
| Unknown | 124 (3.1) | 111 (1.6) |
aWilcoxon rank sum test, normal approximation, two-sided test
Fig. 1Proportion of Prescriptions Filled by Non-VHA Pharmacies in Non-Elderly, Dual-Eligible Veterans, 2010 (N = 5783)
Clinical characteristics of patients according to pharmacy user status, 2010
| Pharmacy user status group ( | ||||
|---|---|---|---|---|
| Characteristic | VHA only | Dual | Non-VHA only | Statistics |
|
|
|
|
| |
| Age, mean (SD) | 53.7 (10.2) | 54.9 (9.7) | 52.5 (10.8) |
|
| Sex, | ||||
| Male | 1125 (96.6) | 1590 (94.5) | 2732 (93.1) |
|
| Female | 40 (3.4) | 93 (5.5) | 203 (6.9) | |
| Residence, | ||||
| Rural | 707 (60.7) | 1080 (64.2) | 1712 (58.3) |
|
| Urban | 449 (38.5) | 593 (35.2) | 1197 (40.8) | |
| Unknown | 9 (0.8) | 10 (0.6) | 26 (0.9) | |
| Service Connection, | ||||
| None | 585 (50.2) | 852 (50.6) | 2070 (70.5) |
|
| 1–10 % | 185 (15.9) | 255 (15.2) | 449 (15.3) | |
| 11–80 % | 369 (31.7) | 523 (31.1) | 331 (11.3) | |
| 81–100 % | 20 (1.7) | 49 (2.9) | 19 (0.7) | |
| Unknown | 6 (0.5) | 4 (0.2) | 66 (2.3) | |
| Prescription fills, mean (SD) | 17.6 (17.2) | 31.7 (25.5) | 21.7 (21.7) |
|
| Outpatient visits, mean (SD) | ||||
| Medical | 14.3 (13.5) | 23.6 (21.9) | 13.6 (16.3) |
|
| Mental health | 1.4 (4.1) | 1.8 (5.5) | 0.7 (5.6) |
|
| Total | 15.7 (14.8) | 25.4 (23.5) | 14.2 (17.5) |
|
| Inpatient admission, | ||||
| Medical | 46 (4.0) | 177 (10.5) | 214 (7.3) |
|
| Mental health | 5 (0.4) | 16 (1.0) | 5 (0.2) |
|
| Any | 50 (4.3) | 191 (11.4) | 219 (7.5) |
|
Most common prescription medications filled in non-VHA pharmacies by dual enrolled patients, FY10
| Pharmacy user status | ||||
|---|---|---|---|---|
| Medicationa | All patients | Dual users | Non-VHA only users | Statistics: dual vs. non-VHA only users |
| Hydrocodone | 963 (20.9) | 347 (20.6) | 616 (21.0) | .09; 1; .766 |
| Amoxicillin | 853 (18.5) | 338 (20.1) | 515 (17.6) | 4.6; 1; .033 |
| Simvastatin | 809 (17.5) | 180 (10.7) | 629 (21.4) | 85; 1; <.001b |
| Azithromycin | 802 (17.4) | 304 (18.1) | 498 (17.0) | .89; 1; .344 |
| Lisinopril | 699 (15.1) | 185 (11.0) | 514 (17.5) | 35; 1; <.001b |
| Omeprazole/esomeprazole | 477 (10.3) | 127 (7.6) | 350 (11.9) | 22; 1; <.001b |
| Prednisone | 429 (9.3) | 173 (10.3) | 256 (8.7) | 3.1; 1; .079 |
| Cephalexin | 422 (9.1) | 172 (10.2) | 250 (8.5) | 3.7; 1; .053 |
| Metoprolol | 391 (8.5) | 105 (6.2) | 286 (9.7) | 17; 1; <.001b |
| Hydrochlorothiazide | 374 (8.1) | 92 (5.5) | 282 (9.6) | 25; 1; <.001b |
| Metformin | 338 (7.3) | 82 (4.9) | 256 (8.7) | 23; 1; <.001b |
| Ciprofloxacin | 313 (6.8) | 129 (7.7) | 184 (6.3) | 3.3; 1; .069 |
| Levofloxacin | 292 (6.3) | 118 (7.0) | 174 (5.9) | 2.1; 1; .146 |
| Cyclobenzaprine | 289 (6.3) | 88 (5.2) | 201 (6.9) | 4.8; 1; .029 |
| Atorvastatin | 243 (5.3) | 41 (2.4) | 202 (6.9) | 42; 1; <.001b |
aIncludes all single agent and combination products that contain the ingredient medication (e.g. lisinopril includes combination formulations with other active ingredients such as hydrochlorothiazide; amoxicillin includes amoxicillin plus clavulanate combination products). Cell counts represent the number of unique patients who received each medication during FY10
bStatistically significant difference based on Bonferroni correction for multiple comparisons (α = 0.0033)
Most common medications dispensed in VHA contrasted with dual enrolled exclusive non-VHA pharmacy users, 2010
| Age group: 18–44 years | |||
| VHA systema |
| Dual enrollees who used non-VHA pharmacies exclusively |
|
| Es/omeprazole | 1792 (17.3) | Hydrocodone | 150 (21.6) |
| Hydrocodone | 1766 (17.0) | Amoxicillin | 140 (20.2) |
| Citalopram | 1554 (15.0) | Azithromycin | 134 (19.3) |
| Ibuprofen | 1292 (12.5) | Prednisone | 73 (10.5) |
| Simvastatin | 1246 (12.0) | Cyclobenzaprine | 72 (10.4) |
| Bupropion | 1165 (11.2) | Cephalexin | 55 (7.9) |
| Trazodone | 1087 (10.5) | Es/omeprazole | 44 (6.3) |
| Tramadol | 1008 (9.7) | Simvastatin | 42 (6.1) |
| Zolpidem | 988 (9.5) | Lisinopril | 40 (5.8) |
| Naproxen | 952 (9.2) | Zolpidem | 39 (5.6) |
| Age group: 45–64 years | |||
| VHA systema |
| Dual enrollees who used non-VHA pharmacies exclusively |
|
| Simvastatin | 14,861 (39.2) | Simvastatin | 587 (26.2) |
| Es/omeprazole | 10,251 (27.0) | Lisinopril | 474 (21.2) |
| Lisinopril | 11,335 (29.9) | Hydrocodone | 466 (20.8) |
| Hydrocodone | 6960 (18.3) | Amoxicillin | 375 (16.7) |
| Metoprolol | 6048 (15.9) | Azithromycin | 364 (16.2) |
| Vardenafil | 5673 (15.0) | Es/omeprazole | 306 (13.7) |
| Metformin | 5670 (14.9) | Metoprolol | 278 (12.4) |
| Hydrochlorothiazide | 5519 (14.5) | Hydrochlorothiazide | 267 (11.9) |
| Amlodipine | 4348 (11.5) | Metformin | 243 (10.8) |
| Albuterol inhaler | 3615 (9.5) | Atorvastatin | 196 (8.8) |
aThe VHA system included all patients receiving care at the 4 VHA medical centers with geographic borders that overlapped with the coverage area of the private health insurance plan. Cell counts represent the number of unique patients who received each medication during FY10